Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Medical Policy Determinations for Pharmacogenetic Tests Among US Health Plans

7 Feb 2025

Abstract excerpt

OBJECTIVES: To evaluate medical policy determinations for pharmacogenetic (PGx) testing for 65 clinically relevant drug-gene pairs and evidence cited to support determinations across major US health plans and laboratory benefit managers (LBMs). STUDY DESIGN: Landscape analysis of available PGx medical policies to determine coverage status of certain drug-gene pairs. METHODS: PGx medical policies as of February 1,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug-Induced Adverse Reactions
Share to Pharmacogenetics and Drug Metabolism

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39977287
DOI: 10.37765/ajmc.2025.89683

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Medical Policy Determinations for Pharmacogenetic Tests Among US Health PlansPMID 39977287Read ↗

Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.Semantic proximity Read ↗

Recommendations for pharmacogenetic testing in clinical practice guidelines in the USSemantic proximity Read ↗

The landscape of pharmacogenetic testing in a US managed care populationSemantic proximity Read ↗

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.Semantic proximity Read ↗

Real-world Clinical Effectiveness, Regulatory Transparency and Payer Coverage: Three Ingredients for Translating Pharmacogenomics into Clinical PracticeSemantic proximity Read ↗

Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United StatesSemantic proximity Read ↗

Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing.Semantic proximity Read ↗

Utilization of genetic testing: Analysis of 4,499 prior authorization requests for molecular genetic tests at four US regional health plansSemantic proximity Read ↗

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Semantic proximity Read ↗

Prevalence and types of inconsistencies in clinical pharmacogenetic recommendations among major U.S. sourcesSemantic proximity Read ↗

How to Transition from Single‐Gene Pharmacogenetic Testing to Preemptive Panel‐Based Testing: A TutorialSemantic proximity Read ↗

Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.